November 12, 2014
Notes: Dorlon, Margaret
Am Surg. 2013 Jul;79(7):676-80.
Author Address: General Surgery Department, Medical University of South Carolina, Charleston, South Carolina, USA. firstname.lastname@example.org
Reference Type: Journal Article
Record Number: 5188Author: Dragovic, G.
Title: Acute pancreatitis in HIV/AIDS patients: an issue of concern
Journal: Asian Pac J Trop Biomed
Short Title: Acute pancreatitis in HIV/AIDS patients: an issue of concern
Alternate Journal: Asian Pacific journal of tropical biomedicine
ISSN: 2221-1691 (Print)
Accession Number: 23730553
Abstract: Pancreatitis is a well-described complication of human immunodeficiency virus (HIV) itself and its combination antiretroviral therapy. Historically, this has been predominantly associated with the usage of nucleoside reverse transcriptase inhibitors such as didanosine and stavudine, but only rarely with the usage of protease inhibitors via the induction of hypertriglyceridemia. Pancreatitis rates in HIV/AIDS population may have been exceedingly high because of the comorbid conditions prevalent in HIV/AIDS patients (e.g. ethanol use and biliary disease), and the use of non-combination antiretroviral therapy medications such as pentamidine, corticosteroids, ketoconazole, sulphonamides, metronidazole, isoniazid and opportunistic infections (e.g. cytomegalovirus, cryptosporidiosis, mycobacterial disease). In resource limited settings, where didanosine and stavudine are widely available in cheaper generic fixed dose combinations it is likely that their usage will remain in the first line HIV treatment in common. In such settings management or estimation of a patient’s risk of pancreatitis still remains an issue of concern.